Navigation Links
Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
Date:10/6/2009

SAN DIEGO, Oct. 6 /PRNewswire/ -- Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the Montgomery Healthcare Conference 2009 in Menlo Park, Calif., today.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.

SOURCE Amira Pharmaceuticals, Inc.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
2. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
3. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
4. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
5. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
6. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
7. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
8. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
9. Amira Pharmaceuticals Appoints First Vice President of Development
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , ... July 19, 2017 , ... ... with a larger audience and increased funds raised to support fine arts programs ... of “Disney Aladdin Kids” in Freed-Hardeman University’s Loyd Auditorium. , More than ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... Health Resources and Services Administration (HRSA) grant to train predoctoral dental students in ... needs in rural and underserved areas. , The Predoctoral Pediatric Training Project (PPTP), ...
(Date:7/20/2017)... ... , ... “Fidget”: a fun-filled, action-packed memoir of adventures. “Fidget” is the creation ... teacher who was a summa cum laude graduate of Gardner Webb University. She has ... After her retirement from public school, Lynn continued to pursue her love for music ...
(Date:7/18/2017)... Falls Church, VA (PRWEB) , ... July 18, ... ... CFR Part 11) , What Strategic Decisions Do You Need to Consider?, ... http://www.fdanews.com/newfinalrule      , 42 CFR Part 11, “Final Rule for Clinical ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Seattle, ... and easy way to clean, scrub and moisturize the back and other hard-to-reach areas ... surgery that limited movement in my upper body, particularly my shoulders. I found it ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Research Corp., also known as ,The Epigenetics Company, announced today the release ... manner using the myDNAge ™ test. Based on Horvath,s Clock, so ... and biostatistics at the David Geffen School of Medicine at UCLA ... DNAge ™ technology is used to analyze DNA methylation patterns of ... ...
(Date:7/11/2017)... -- Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe and ... painful intercourse and other painful pelvic pain conditions such as pelvic floor ... ... ... -based start-up company, VuVatech LLC, fills a void in the women,s ...
(Date:7/10/2017)... 2017  BDI Group subsidiary Pathway Purchasing Network, ... organization serving specialty pharmacies, home infusion companies and ... significant, value-added member programs designed to help organizations ... and improve access and affordability for patients who ... Pathway has worked ...
Breaking Medicine Technology: